Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
INDIANAPOLIS, Sept. 21, 2016 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated with the human microbiome, today reported its participation in recent HBV scientific meetings in Asia.
Earlier today, Assembly’s Qi Huang, PhD, presented preclinical data on the company’s Core Protein Allosteric Modifiers (CpAMs) at the 2016 International HBV Meeting in Seoul, South Korea, in an oral session co-chaired by Assembly scientific co-founder Dr. Adam Zlotnick. Assembly’s CpAMs are direct acting oral compounds that allosterically modulate HBV core protein, an essential viral protein involved in multiple critical functions throughout the HBV lifecycle.
Assembly researchers also participated in the 2nd Nanjing International Symposium on Oncogenic Viruses & Drug Discovery and Development held in Nanjing, China, September 16-18, 2016. In addition, Assembly’s Chief Scientific Officer, Richard Colonno, PhD, gave a presentation on the company’s HBV program at Nanfang Hospital in Guangzhou, China, Nanfang Hospital is an affiliate of Southern Medical University, one of the premier academic medical institutions in China.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV-cure program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biological therapeutics addressing diseases associated with the human microbiome. Assembly's HBV-cure program aims to increase the current low cure rates for chronic HBV. The company’s highly experienced HBV team has collectively brought more than 10 anti-infective products to the market. They are pursuing several drug candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. The company’s microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICELTM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, ABI-M101, is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. For more information, visit assemblybio.com.
Contacts Corporate: Assembly Biosciences, Inc. David Barrett [email protected] Media: Barbara Lindheim 212 584-2276 [email protected]
